Kaser Arthur, Tilg Herbert
Medical University Innsbruck, Division of Gastroenterology and Hepatology, Innsbruck, Austria.
Expert Opin Ther Targets. 2008 May;12(5):553-63. doi: 10.1517/14728222.12.5.553.
Advances in mucosal immunology have revealed a broad set of new therapeutic targets to resolve inflammation and symptoms in patients with inflammatory bowel diseases (IBD).
Despite the enormous success of anti-TNF therapies in IBD, these treatments have limited efficacy, and there continues to be concerns regarding their toxicity. Thus, a considerable unmet need exists for better treatment of these disorders.
New therapeutic targets include other pro-inflammatory cytokines such as IL-6, IL-12, IL-17 or IFN-gamma, and others. In addition, molecules directing trafficking of inflammatory cells such as integrin alpha(4)beta(7) or intracellular adhesion molecule 1 (ICAM-1) might be attractive candidates as anti-inflammatory targets. Targeting intestine-specific homing by blocking chemokine receptors such as CCR9 might provide a new avenue for treatment in the future.
All these and many other different therapies are currently being investigated in IBD, the challenge will be to develop more effective therapies than those currently available.
黏膜免疫学的进展揭示了一系列广泛的新治疗靶点，以解决炎症性肠病（IBD）患者的炎症和症状。
尽管抗TNF疗法在IBD中取得了巨大成功，但这些治疗的疗效有限，并且人们对其毒性仍存在担忧。因此，对于更好地治疗这些疾病存在相当大的未满足需求。
新的治疗靶点包括其他促炎细胞因子，如IL-6、IL-12、IL-17或IFN-γ等。此外，指导炎症细胞运输的分子，如整合素α4β7或细胞间黏附分子1（ICAM-1），可能是有吸引力的抗炎靶点。通过阻断趋化因子受体（如CCR9）来靶向肠道特异性归巢，可能为未来的治疗提供新途径。
目前所有这些以及许多其他不同的疗法都在IBD中进行研究，挑战将是开发比现有疗法更有效的疗法。
